Skip to main content
. 2022 Apr 11;14(8):1928. doi: 10.3390/cancers14081928

Table 2.

Perioperative and pathological data of patients undergoing operation for MEN1-ZES.

Parameter ALL
(n = 35)
PD
(n = 11)
Thompson
(n = 12)
DUODX
(n = 12)
p-Value
PD vs. Non-PD *
Pts. with complications Dindo ≥ 3 12/35 (37%) 4/11 (36%) 3/12 (25%) 5/12 (42%) 0.433
POPF Typ B 1/35 (3%) 1/11 (9%) 0/12 0/12 0.341
POPF Type C 2/35 (6%) 1/11 (9%) 0/12 1/12 (8%) 0.574
Postoperative bleeding 4/35 (11%) 0/11 2/12 (17%) 2/12 (17%) 0.043
Postoperative pancreatitis 2/35 (6%) 1/11 (9%) 0/12 1/12 (8%) 0.574
Reoperation due to complications 8/35 (20%) 2/11 (18%) 3/12 (17%) 3/12 (25%) 0.667
Perioperative mortality 0/35 0/11 0/12 0/12 1
No. of pNENs in specimen (median/range) 3 (0–18) 4 (0–18) 3 (1–7) 1 (0–3) 0.255
No. duodenal gastrinomas
(median/range)
3 (1–13) 3 (1–8) 2 (1–13) 3 (1–6) 0.430
No. resected lymph nodes (median/range) 11 (3–25) 15 (3–25) 14 (8–20) 9 (6–12) 0.279
Lymph node ratio (affected/analyzed) 0.07 0.13 0.07 0.11 0.626
Postop. normal serum gastrin (<125 pg/mL) 30/35 (86%) 10/11 (91%) 10/12 (83%) 10/12 (83%) 0.566
Postoperative Diabetes mellitus # 0/35 0/11 0/12 0/12 1

pNEN = pancreaticoduodenal neuroendocrine neoplasm; PD = pancreaticoduodenectomy; DUODX + LAD = duodenotomy, excision of duodenal gastrinomas, and lymphadenectomy; POPF = postoperative pancreatic fistula; * non-PD includes both Thompson and DUODX resections; # in the first 30 postoperative days.